Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
ACXP
Acurx Pharmaceuticals
$0.37
Chart
0.39
0.75
0.85
2.51
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
ACXP
Acurx Pharmaceuticals
$0.37
Chart
0.39
0.75
0.85
2.51
ACXP Latest Headlines
Acurx Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 13 2025 Conference Call and Provide Business Update. STATEN ISLAND N.Y. April 30 2025 /PRNewswire/ -- Acurx Pharmaceuticals Inc. (NASDAQ: ACXP) (Acurx or the Company) a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections announced today that the Company will...
Wed Apr 30, 2025
Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase. STATEN ISLAND N.Y. April 28 2025 /PRNewswire/ -- Acurx Pharmaceuticals (Nasdaq: ACXP) (Acurx or the Company) a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections today announced that David P. Luci...
Mon Apr 28, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
ACXP Stock trends
ACXP Stock performance
ACXP Stock analysis
ACXP investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Don't Be a Sheep, Be a StocksRunner
StocksRunner Aggregates The Most Important Headlines Into A Single Credibility Score
Sign up for free and
continue analysing ACXP
Already a Member? Click here to Login
Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.
Don't Be a Sheep, Be a StocksRunner
StocksRunner Aggregates The Most Important Headlines Into A Single Credibility Score
Sign up for free and
continue analysing ACXP
Already a Member? Click here to Login
Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.
Login to display Acurx Pharmaceuticals (ACXP) recommendation from the last 90 days from financial news and social media.
Hover over the category for more information
